> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Warns USV About CGMP Violations at Daman
- URL: https://www.fdaweb.com/fda-warns-usv-about-cgmp-violations-at-daman/
- Published: 2017-03-23T12:00:00.000Z
- Updated: 2026-09-14T22:13:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138282

FDA has sent a Warning Letter to India’s USV Pvt Ltd for CGMP violations and data integrity problems at its Daman drug manufacturing facility. *The Economic Times* [reports](http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-issues-warning-letter-to-usv-pvt-over-daman-plant/articleshow/57792954.cms?ref=fdaweb.com) the letter also referenced similar CGMP violations at the firm’s other facilities. FDA acknowledged that USV is using a consultant to audit its operation and assist in meeting regulatory requirements. The agency said the company’s quality unit “does not adequately ensure the accuracy and integrity of data to support safety, effectiveness, and quality of the drugs you manufacture.” It also said that the repeated problems at multiple sites demonstrate that USV’s oversight and control over the manufacturing of drugs is inadequate.